Elanco Animal Health (ELAN) Financials

$13.20 +0.54 (+4.27%)

Closing price 05/27/2025 03:59 PM Eastern

Extended Trading

$13.18 -0.02 (-0.15%)

As of 04:14 AM Eastern

Annual Income Statements for Elanco Animal Health

This table shows Elanco Animal Health's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016
Net Income / (Loss) Attributable to Common Shareholders	338	-1,231	-78	-483	-574	68	87	-311	-48
Consolidated Net Income / (Loss)	338	-1,231	-78	-483	-574	68	87	-311	-48
Net Income / (Loss) Continuing Operations	338	-1,231	-78	-483	-574	68	87	-311	-48
Total Pre-Tax Income	488	-1,195	-72	-571	-677	78	114	-233	-22
Total Operating Income	83	-918	169	-335	-705	185	144	-233	-25
Total Gross Profit	2,436	2,486	2,498	2,632	1,604	1,601	1,493	1,395	1,505
Total Revenue	4,439	4,417	4,411	4,764	3,271	3,071	3,067	2,889	2,914
Operating Revenue	4,439	4,417	4,411	4,764	3,271	3,071	3,067	2,889	2,914
Total Cost of Revenue	2,003	1,931	1,913	2,132	1,667	1,470	1,574	1,494	1,409
Operating Cost of Revenue	2,003	1,931	1,913	2,132	1,667	1,470	1,574	1,494	1,409
Total Operating Expenses	2,353	3,404	2,329	2,967	2,309	1,416	1,349	1,628	1,530
Selling, General & Admin Expense	1,314	1,285	1,265	1,403	997	760	735	780	785
Research & Development Expense	344	327	321	369	329	270	247	252	266
Amortization Expense	527	548	528	556	360	200	197	221	171
Other Operating Expenses / (Income)	18	75	32	5.00	-	-	41	-	-
Impairment Charge	0.00	1,042	0.00	0.00	-	-	-	-	-
Restructuring Charge	150	127	183	634	623	186	129	375	308
Total Other Income / (Expense), net	405	-277	-241	-236	28	-107	-30	0.10	2.80
Interest Expense	235	277	241	236	150	79	30	0.00	0.00
Other Income / (Expense), net	640	0.00	0.00	-	178	-28	-	0.10	2.80
Income Tax Expense	150	36	6.00	-88	-103	10	28	78	26
Basic Earnings per Share	$0.68	($2.50)	($0.16)	($0.99)	($1.30)	$0.18	$0.28	($1.06)	($0.16)
Weighted Average Basic Shares Outstanding	494M	492.30M	488.30M	487.20M	441.40M	369M	313.70M	293.30M	293.30M
Diluted Earnings per Share	$0.68	($2.50)	($0.16)	($0.99)	($1.30)	$0.18	$0.28	($1.06)	($0.16)
Weighted Average Diluted Shares Outstanding	497.30M	492.30M	488.30M	487.20M	441.40M	370.30M	313.70M	293.30M	293.30M
Weighted Average Basic & Diluted Shares Outstanding	494.61M	492.97M	491.54M	473.19M	472.17M	398.53M	313.70M	293.30M	293.30M

This table shows Elanco Animal Health's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	67	-8.00	364	-50	32	-141	-1,096	-97	103	-54	-65
Consolidated Net Income / (Loss)	67	-8.00	364	-50	32	-141	-1,096	-97	103	-54	-65
Net Income / (Loss) Continuing Operations	67	-8.00	364	-50	32	-141	-1,096	-97	103	-54	-65
Total Pre-Tax Income	60	-51	559	-32	12	-127	-1,097	-79	108	-89	-44
Total Operating Income	112	-646	618	33	78	-78	-1,016	-5.00	181	-30	16
Total Gross Profit	684	519	538	689	690	519	581	623	763	536	554
Total Revenue	1,193	1,020	1,030	1,184	1,205	1,035	1,068	1,057	1,257	984	1,026
Operating Revenue	1,193	1,020	1,030	1,184	1,205	1,035	1,068	1,057	1,257	984	1,026
Total Cost of Revenue	509	501	492	495	515	516	487	434	494	448	472
Operating Cost of Revenue	509	501	492	495	515	516	487	434	494	448	472
Total Operating Expenses	572	1,165	-80	656	612	597	1,597	628	582	566	538
Selling, General & Admin Expense	341	300	323	354	337	292	313	353	327	301	298
Research & Development Expense	94	81	87	89	87	79	86	81	81	80	78
Amortization Expense	128	130	133	131	133	138	140	136	134	130	128
Restructuring Charge	9.00	7.00	17	80	46	36	16	35	40	31	26
Total Other Income / (Expense), net	-52	595	-59	-65	-66	-49	-81	-74	-73	-59	-60
Interest Expense	40	46	58	65	66	67	72	74	64	62	60
Other Income / (Expense), net	-12	-	-1.00	-	-	-	-9.00	-	-9.00	-	-
Income Tax Expense	-7.00	-43	195	18	-20	14	-1.00	18	5.00	-35	21
Basic Earnings per Share	$0.14	($0.02)	$0.74	($0.10)	$0.06	($0.29)	($2.22)	($0.20)	$0.21	($0.11)	($0.13)
Weighted Average Basic Shares Outstanding	495.10M	494M	494.30M	494.20M	493.20M	492.30M	492.70M	492.60M	491.10M	488.30M	488.40M
Diluted Earnings per Share	$0.13	($0.01)	$0.73	($0.10)	$0.06	($0.29)	($2.22)	($0.20)	$0.21	($0.11)	($0.13)
Weighted Average Diluted Shares Outstanding	499.10M	497.30M	497.70M	494.20M	496M	492.30M	492.70M	492.60M	492.80M	488.30M	488.40M
Weighted Average Basic & Diluted Shares Outstanding	496.65M	494.61M	494.35M	494.33M	494.18M	492.97M	492.80M	492.68M	492.55M	491.54M	474.21M

This table details how cash moves in and out of Elanco Animal Health's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016
Net Change in Cash & Equivalents	116	7.00	-293	132	161	-333	325	57	-176
Net Cash From Operating Activities	541	271	452	483	-41	224	487	174	156
Net Cash From Continuing Operating Activities	541	271	452	483	-41	224	487	174	156
Net Income / (Loss) Continuing Operations	338	-1,231	-78	-483	-574	68	87	-311	-48
Consolidated Net Income / (Loss)	338	-1,231	-78	-483	-574	68	87	-311	-48
Depreciation Expense	662	694	682	716	517	314	296	318	254
Non-Cash Adjustments To Reconcile Net Income	-499	1,177	367	263	-146	82	146	116	119
Changes in Operating Assets and Liabilities, net	40	-369	-519	-77	72	-241	-41	50	-169
Net Cash From Investing Activities	1,158	-169	-179	-530	-4,779	-235	-127	-965	-182
Net Cash From Continuing Investing Activities	1,158	-169	-179	-530	-4,779	-235	-127	-965	-182
Purchase of Property, Plant & Equipment	-147	-140	-171	-159	-135	-140	-135	-99	-110
Acquisitions	-55	-33	-13	-380	-5,177	-90	-2.00	-901	-45
Divestitures	1,294	0.00	0.00	-	435	0.00	0.00	-	-
Other Investing Activities, net	66	4.00	5.00	9.00	26	-5.00	0.10	-3.00	-34
Net Cash From Financing Activities	-1,492	-83	-549	210	4,954	-305	-35	848	-150
Net Cash From Continuing Financing Activities	-1,492	-83	-549	210	4,954	-305	-35	848	-150
Repayment of Debt	-2,062	-683	-1,522	-854	-1,070	-113	-49	-0.80	0.00
Issuance of Debt	570	600	988	500	4,804	0.00	2,500	0.00	0.00
Other Financing Activities, net	0.00	0.00	-15	64	0.00	-192	-4,146	848	-150
Effect of Exchange Rate Changes	-91	-12	-17	-31	27	-17	-	-	-

This table details how cash moves in and out of Elanco Animal Health's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	19	-22	74	71	-7.00	-17	2.00	49	-27	-115	-47
Net Cash From Operating Activities	-4.00	177	162	200	2.00	157	198	61	-145	13	189
Net Cash From Continuing Operating Activities	-4.00	177	162	200	2.00	157	198	61	-145	13	189
Net Income / (Loss) Continuing Operations	67	-8.00	364	-50	32	-141	-1,096	-97	103	-54	-65
Consolidated Net Income / (Loss)	67	-8.00	364	-50	32	-141	-1,096	-97	103	-54	-65
Depreciation Expense	161	164	170	162	166	171	173	177	173	168	167
Non-Cash Adjustments To Reconcile Net Income	15	20	-605	75	11	42	1,114	9.00	12	35	88
Changes in Operating Assets and Liabilities, net	-247	1.00	233	13	-207	85	7.00	-28	-433	-136	-1.00
Net Cash From Investing Activities	-58	-90	1,244	-33	37	-35	-36	-43	-55	-76	-37
Net Cash From Continuing Investing Activities	-58	-90	1,244	-33	37	-35	-36	-43	-55	-76	-37
Purchase of Property, Plant & Equipment	-65	-47	-42	-34	-24	-41	-33	-42	-24	-77	-36
Divestitures	9.00	-	1,228	-	66	-	-	-	0.00	-	-
Other Investing Activities, net	-2.00	-1.00	66	1.00	0.00	6.00	-	-1.00	-1.00	3.00	9.00
Net Cash From Financing Activities	52	-32	-1,340	-93	-27	-139	-157	39	174	-84	-169
Net Cash From Continuing Financing Activities	52	-32	-1,340	-93	-27	-139	-157	39	174	-84	-170
Repayment of Debt	-198	-32	-1,690	-213	-127	-139	-507	-11	-26	-69	-170
Issuance of Debt	250	-	350	120	100	-	350	50	200	-	-
Effect of Exchange Rate Changes	29	-77	8.00	-3.00	-19	-	-3.00	-	-	-	-

This table presents Elanco Animal Health's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017
Total Assets	12,614	14,362	15,491	16,478	17,693	8,986	8,957	8,940
Total Current Assets	3,215	3,407	3,279	3,274	3,417	2,373	2,505	2,124
Cash & Equivalents	468	352	345	638	495	334	475	323
Accounts Receivable	886	1,010	1,002	1,028	1,077	890	709	602
Inventories, net	1,574	1,735	1,538	1,371	1,578	1,051	1,004	1,062
Prepaid Expenses	287	310	394	237	256	87	114	136
Plant, Property, & Equipment, net	993	1,026	999	1,055	1,316	955	922	920
Total Noncurrent Assets	8,406	9,929	11,213	12,149	12,960	5,657	5,529	5,896
Goodwill	4,414	5,094	5,993	6,172	6,225	2,990	2,958	2,969
Intangible Assets	3,681	4,494	4,842	5,587	6,387	2,483	2,505	2,673
Other Noncurrent Operating Assets	311	341	378	390	348	185	67	254
Total Liabilities & Shareholders' Equity	12,614	14,362	15,491	16,478	17,693	8,986	8,957	8,940
Total Liabilities	6,518	8,139	8,202	8,970	9,217	3,439	3,759	1,160
Total Current Liabilities	1,315	1,241	1,702	1,647	2,077	819	971	643
Short-Term Debt	44	38	388	294	555	25	29	0.00
Accounts Payable	296	270	390	416	501	239	474	204
Current Deferred Revenue	332	367	324	-	-	-	-	-
Current Employee Benefit Liabilities	177	157	146	185	144	100	99	89
Other Current Liabilities	466	409	454	752	877	455	369	350
Total Noncurrent Liabilities	5,203	6,898	6,500	7,323	7,140	2,620	2,789	517
Long-Term Debt	4,277	5,736	5,448	6,025	5,572	2,331	2,443	0.00
Noncurrent Deferred & Payable Income Tax Liabilities	449	567	662	765	900	101	115	252
Noncurrent Employee Benefit Liabilities	175	184	161	271	346	83	109	139
Other Noncurrent Operating Liabilities	302	411	229	262	322	107	122	126
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	6,096	6,223	7,289	7,508	8,476	5,547	5,198	7,780
Total Preferred & Common Equity	6,096	6,223	7,289	7,508	8,476	5,547	5,198	7,780
Total Common Equity	6,096	6,223	7,289	7,508	8,476	5,547	5,198	7,780
Common Stock	8,817	8,777	8,738	8,696	8,650	5,636	5,403	0.00
Retained Earnings	-1,950	-2,288	-1,057	-979	-477	84	16	0.00
Accumulated Other Comprehensive Income / (Loss)	-771	-266	-392	-209	303	-174	-222	-257

This table presents Elanco Animal Health's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	12,941	13,283	13,764	14,019	14,344	15,796	15,769	14,948
Total Current Assets	3,440	3,366	4,011	4,050	3,565	3,652	3,548	3,154
Cash & Equivalents	487	490	416	345	369	367	318	460
Accounts Receivable	1,060	904	1,080	1,078	1,135	1,225	1,264	1,028
Inventories, net	1,592	1,632	1,611	1,638	1,690	1,690	1,596	1,340
Prepaid Expenses	301	340	277	338	371	370	370	326
Plant, Property, & Equipment, net	1,047	979	949	949	992	1,007	1,000	936
Total Noncurrent Assets	8,454	8,938	8,804	9,020	9,787	11,137	11,221	10,858
Goodwill	4,508	4,625	4,480	4,478	4,902	6,040	6,061	5,716
Intangible Assets	3,634	4,011	4,000	4,196	4,475	4,678	4,791	4,766
Other Noncurrent Operating Assets	312	302	324	346	410	419	369	376
Total Liabilities & Shareholders' Equity	12,941	13,283	13,764	14,019	14,344	15,796	15,769	14,948
Total Liabilities	6,588	6,760	7,822	7,963	8,210	8,376	8,289	8,203
Total Current Liabilities	1,269	1,321	1,370	1,232	1,265	1,284	1,578	1,613
Short-Term Debt	44	44	213	38	39	39	381	394
Accounts Payable	330	259	291	302	296	354	381	350
Current Deferred Revenue	319	333	356	318	356	332	-	-
Other Current Liabilities	576	685	510	574	574	559	706	733
Total Noncurrent Liabilities	5,319	5,439	6,452	6,731	6,945	7,092	6,711	6,590
Long-Term Debt	4,351	4,313	5,463	5,727	5,870	6,023	5,639	5,507
Noncurrent Deferred & Payable Income Tax Liabilities	481	539	524	530	643	658	663	618
Other Noncurrent Operating Liabilities	487	587	465	474	432	411	245	225
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	6,353	6,523	5,942	6,056	6,134	7,420	7,480	6,745
Total Preferred & Common Equity	6,353	6,523	5,942	6,056	6,134	7,420	7,480	6,745
Total Common Equity	6,353	6,523	5,942	6,056	6,134	7,420	7,480	6,745
Common Stock	8,819	8,804	8,790	8,777	8,763	8,752	8,744	8,724
Retained Earnings	-1,883	-1,942	-2,306	-2,256	-2,147	-1,051	-954	-972
Accumulated Other Comprehensive Income / (Loss)	-583	-339	-542	-465	-482	-281	-310	-1,007

This table displays calculated financial ratios and metrics derived from Elanco Animal Health's official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016
Growth Metrics	-	-	-	-	-	-	-	-	-
Revenue Growth	0.50%	0.14%	-7.41%	45.64%	6.51%	0.14%	6.15%	-0.84%	0.00%
EBITDA Growth	718.30%	-126.32%	91.24%	456.25%	-83.05%	7.35%	412.47%	-63.02%	0.00%
EBIT Growth	178.76%	-643.20%	150.45%	36.43%	-435.67%	9.26%	161.78%	-938.39%	0.00%
NOPAT Growth	108.95%	-643.20%	150.45%	52.48%	-405.99%	48.05%	166.88%	-823.41%	0.00%
Net Income Growth	127.46%	-1,478.21%	83.85%	15.85%	-944.12%	-21.39%	127.84%	-548.64%	0.00%
EPS Growth	127.20%	-1,462.50%	83.84%	23.85%	-822.22%	-35.71%	126.42%	-562.50%	0.00%
Operating Cash Flow Growth	99.63%	-40.04%	-6.42%	1,278.05%	-118.30%	-54.03%	180.38%	11.48%	0.00%
Free Cash Flow Firm Growth	256.11%	-6.62%	-21.71%	109.58%	-1,644.39%	-170.30%	107.53%	0.00%	0.00%
Invested Capital Growth	-14.56%	-8.88%	-3.10%	-6.44%	86.55%	8.07%	-6.23%	0.00%	0.00%
Revenue Q/Q Growth	-0.34%	1.17%	-2.82%	-0.52%	11.98%	-0.40%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	4.92%	-25.14%	3.78%	30.88%	869.23%	4.13%	0.00%	0.00%	0.00%
EBIT Q/Q Growth	11.06%	-5.52%	28.03%	38.53%	-35.72%	5.72%	0.00%	0.00%	0.00%
NOPAT Q/Q Growth	-82.25%	-5.52%	28.03%	38.53%	-81.56%	-7.02%	0.00%	0.00%	0.00%
Net Income Q/Q Growth	64.88%	-7.60%	40.91%	32.16%	-132.95%	-27.51%	0.00%	0.00%	0.00%
EPS Q/Q Growth	70.00%	-7.76%	42.86%	34.87%	-124.14%	-30.77%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	3.84%	113.39%	-31.72%	189.22%	-123.01%	-5.60%	37.46%	0.00%	0.00%
Free Cash Flow Firm Q/Q Growth	9.05%	607.63%	-64.11%	614.91%	-7.25%	0.00%	0.00%	0.00%	0.00%
Invested Capital Q/Q Growth	-4.24%	-0.25%	4.87%	-2.76%	2.05%	0.39%	0.00%	0.00%	0.00%
Profitability Metrics	-	-	-	-	-	-	-	-	-
Gross Margin	54.88%	56.28%	56.63%	55.25%	49.04%	52.13%	48.68%	48.29%	51.64%
EBITDA Margin	31.20%	-5.07%	19.29%	9.34%	2.45%	15.37%	14.34%	2.97%	7.96%
Operating Margin	1.87%	-20.78%	3.83%	-7.03%	-21.55%	6.02%	4.69%	-8.05%	-0.86%
EBIT Margin	16.29%	-20.78%	3.83%	-7.03%	-16.11%	5.11%	4.69%	-8.05%	-0.77%
Profit (Net Income) Margin	7.61%	-27.87%	-1.77%	-10.14%	-17.55%	2.21%	2.82%	-10.75%	-1.64%
Tax Burden Percent	69.26%	103.01%	108.33%	84.59%	84.79%	87.18%	75.81%	133.58%	213.84%
Interest Burden Percent	67.50%	130.17%	-42.60%	170.45%	128.46%	49.68%	79.40%	100.00%	100.00%
Effective Tax Rate	30.74%	0.00%	0.00%	0.00%	0.00%	12.82%	24.19%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.53%	-5.26%	0.91%	-1.72%	-4.56%	2.22%	1.51%	-4.37%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	6.58%	-16.05%	-2.60%	-6.12%	-6.67%	-2.69%	-1.54%	87.04%	0.00%
Return on Net Nonoperating Assets (RNNOA)	4.96%	-12.96%	-1.97%	-4.32%	-3.63%	-0.95%	-0.17%	-3.62%	0.00%
Return on Equity (ROE)	5.49%	-18.22%	-1.05%	-6.04%	-8.19%	1.27%	1.33%	-7.99%	0.00%
Cash Return on Invested Capital (CROIC)	16.24%	4.03%	4.06%	4.94%	-64.97%	-5.54%	7.94%	-204.37%	0.00%
Operating Return on Assets (OROA)	5.36%	-6.15%	1.06%	-1.96%	-3.95%	1.75%	1.61%	-2.60%	0.00%
Return on Assets (ROA)	2.51%	-8.25%	-0.49%	-2.83%	-4.30%	0.76%	0.97%	-3.48%	0.00%
Return on Common Equity (ROCE)	5.49%	-18.22%	-1.05%	-6.04%	-8.19%	1.27%	1.33%	-7.99%	0.00%
Return on Equity Simple (ROE_SIMPLE)	5.54%	-19.78%	-1.07%	-6.43%	-6.77%	1.23%	1.66%	-3.99%	0.00%
Net Operating Profit after Tax (NOPAT)	57	-643	118	-235	-494	161	109	-163	-18
NOPAT Margin	1.30%	-14.55%	2.68%	-4.92%	-15.09%	5.25%	3.55%	-5.64%	-0.61%
Net Nonoperating Expense Percent (NNEP)	-6.05%	10.78%	3.51%	4.40%	2.11%	4.90%	3.05%	-91.41%	0.00%
Return On Investment Capital (ROIC_SIMPLE)	0.55%	-5.36%	0.90%	-	-	-	-	-	-
Cost of Revenue to Revenue	45.12%	43.72%	43.37%	44.75%	50.96%	47.87%	51.32%	51.71%	48.36%
SG&A Expenses to Revenue	29.60%	29.09%	28.68%	29.45%	30.48%	24.75%	23.97%	26.99%	26.94%
R&D to Revenue	7.75%	7.40%	7.28%	7.75%	10.06%	8.79%	8.04%	8.71%	9.12%
Operating Expenses to Revenue	53.01%	77.07%	52.80%	62.28%	70.59%	46.11%	44.00%	56.34%	52.50%
Earnings before Interest and Taxes (EBIT)	723	-918	169	-335	-527	157	144	-233	-22
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	1,385	-224	851	445	80	472	440	86	232
Valuation Ratios	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.98	1.18	0.80	1.79	1.71	1.98	2.22	0.19	0.00
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	147.45	0.00	0.71	0.00
Price to Revenue (P/Rev)	1.35	1.66	1.31	2.82	4.42	3.58	3.76	0.52	0.52
Price to Earnings (P/E)	17.71	0.00	0.00	0.00	0.00	161.54	133.27	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	5.65%	0.00%	0.00%	0.00%	0.00%	0.62%	0.75%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.99	1.10	0.88	1.45	1.43	1.72	1.91	0.16	0.00
Enterprise Value to Revenue (EV/Rev)	2.22	2.89	2.56	4.01	6.14	4.23	4.34	0.41	0.00
Enterprise Value to EBITDA (EV/EBITDA)	7.10	0.00	13.26	42.94	251.18	27.53	30.30	13.83	0.00
Enterprise Value to EBIT (EV/EBIT)	13.61	0.00	66.78	0.00	0.00	82.77	92.71	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	171.16	0.00	95.40	0.00	0.00	80.57	122.30	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	18.19	47.10	24.97	39.56	0.00	58.01	27.34	6.83	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	5.61	25.92	21.40	28.37	0.00	0.00	23.23	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-
Debt to Equity	0.71	0.93	0.80	0.84	0.72	0.42	0.48	0.00	0.00
Long-Term Debt to Equity	0.70	0.92	0.75	0.80	0.66	0.42	0.47	0.00	0.00
Financial Leverage	0.75	0.81	0.76	0.71	0.54	0.35	0.11	-0.04	0.00
Leverage Ratio	2.19	2.21	2.16	2.14	1.90	1.67	1.38	1.15	0.00
Compound Leverage Factor	1.48	2.88	-0.92	3.64	2.44	0.83	1.10	1.15	0.00
Debt to Total Capital	41.48%	48.13%	44.46%	45.70%	41.96%	29.80%	32.23%	0.00%	0.00%
Short-Term Debt to Total Capital	0.42%	0.32%	2.96%	2.13%	3.80%	0.31%	0.38%	0.00%	0.00%
Long-Term Debt to Total Capital	41.06%	47.81%	41.51%	43.57%	38.16%	29.49%	31.86%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	58.52%	51.87%	55.54%	54.30%	58.04%	70.20%	67.77%	100.00%	0.00%
Debt to EBITDA	3.12	-25.78	6.86	14.20	76.59	4.99	5.62	0.00	0.00
Net Debt to EBITDA	2.78	-24.21	6.45	12.77	70.26	4.26	4.08	0.00	0.00
Long-Term Debt to EBITDA	3.09	-25.61	6.40	13.54	69.65	4.94	5.56	0.00	0.00
Debt to NOPAT	75.16	-8.99	49.33	-26.95	-12.42	14.60	22.69	0.00	0.00
Net Debt to NOPAT	67.02	-8.44	46.42	-24.23	-11.39	12.46	16.48	0.00	0.00
Long-Term Debt to NOPAT	74.40	-8.93	46.05	-25.69	-11.29	14.45	22.43	0.00	0.00
Altman Z-Score	1.06	0.60	0.77	1.16	1.08	2.54	2.44	1.22	0.00
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-
Current Ratio	2.44	2.75	1.93	1.99	1.65	2.90	2.58	3.30	0.00
Quick Ratio	1.03	1.10	0.79	1.01	0.76	1.50	1.22	1.44	0.00
Cash Flow Metrics	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	1,753	492	527	674	-7,034	-403	574	-7,620	0.00
Operating Cash Flow to CapEx	368.03%	193.57%	264.33%	303.77%	-65.08%	160.00%	389.53%	284.92%	151.51%
Free Cash Flow to Firm to Interest Expense	7.46	1.78	2.19	2.85	-46.89	-5.10	19.38	0.00	0.00
Operating Cash Flow to Interest Expense	2.30	0.98	1.88	2.05	-0.27	2.84	16.46	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	1.68	0.47	1.17	1.37	-0.69	1.06	12.24	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-
Asset Turnover	0.33	0.30	0.28	0.28	0.25	0.34	0.34	0.32	0.00
Accounts Receivable Turnover	4.68	4.39	4.35	4.53	3.33	3.84	4.68	4.80	0.00
Inventory Turnover	1.21	1.18	1.32	1.45	1.27	1.43	1.52	1.41	0.00
Fixed Asset Turnover	4.40	4.36	4.30	4.02	2.88	3.27	3.33	3.14	0.00
Accounts Payable Turnover	7.08	5.85	4.75	4.65	4.51	4.12	4.64	7.33	0.00
Days Sales Outstanding (DSO)	77.95	83.13	83.99	80.64	109.74	95.04	78.03	76.04	0.00
Days Inventory Outstanding (DIO)	301.49	309.33	277.52	252.44	287.79	255.10	239.62	259.55	0.00
Days Payable Outstanding (DPO)	51.57	62.38	76.89	78.50	81.01	88.51	78.59	49.79	0.00
Cash Conversion Cycle (CCC)	327.87	330.09	284.61	254.58	316.51	261.64	239.07	285.80	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-
Invested Capital	9,949	11,645	12,780	13,189	14,097	7,557	6,992	7,457	0.00
Invested Capital Turnover	0.41	0.36	0.34	0.35	0.30	0.42	0.42	0.77	0.00
Increase / (Decrease) in Invested Capital	-1,696	-1,135	-409	-908	6,540	565	-465	7,457	0.00
Enterprise Value (EV)	9,840	12,765	11,286	19,108	20,095	12,995	13,323	1,186	0.00
Market Capitalization	5,987	7,343	5,795	13,427	14,474	10,985	11,528	1,510	1,510
Book Value per Share	$12.33	$12.63	$15.37	$15.87	$17.96	$14.87	$14.22	$26.53	$0.00
Tangible Book Value per Share	($4.04)	($6.83)	($7.48)	($8.99)	($8.76)	$0.20	($0.73)	$7.29	$0.00
Total Capital	10,417	11,997	13,125	13,827	14,603	7,902	7,670	7,780	0.00
Total Debt	4,321	5,774	5,836	6,319	6,127	2,355	2,472	0.00	0.00
Total Long-Term Debt	4,277	5,736	5,448	6,025	5,572	2,331	2,443	0.00	0.00
Net Debt	3,853	5,422	5,491	5,681	5,621	2,010	1,795	-323	0.00
Capital Expenditures (CapEx)	147	140	171	159	63	140	125	61	103
Debt-free, Cash-free Net Working Capital (DFCFNWC)	1,476	1,852	1,620	1,283	1,389	1,234	886	1,157	0.00
Debt-free Net Working Capital (DFNWC)	1,944	2,204	1,965	1,921	1,895	1,579	1,563	1,481	0.00
Net Working Capital (NWC)	1,900	2,166	1,577	1,627	1,340	1,555	1,534	1,481	0.00
Net Nonoperating Expense (NNE)	-281	588	196	249	81	93	22	148	30
Net Nonoperating Obligations (NNO)	3,853	5,422	5,491	5,681	5,621	2,010	1,795	-323	0.00
Total Depreciation and Amortization (D&A)	662	694	682	780	607	315	296	318	254
Debt-free, Cash-free Net Working Capital to Revenue	33.25%	41.93%	36.73%	26.93%	42.46%	40.18%	28.88%	40.06%	0.00%
Debt-free Net Working Capital to Revenue	43.79%	49.90%	44.55%	40.32%	57.93%	51.42%	50.97%	51.25%	0.00%
Net Working Capital to Revenue	42.80%	49.04%	35.75%	34.15%	40.97%	50.62%	50.03%	51.25%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.68	($2.50)	$0.00	($0.97)	($1.27)	$0.18	$0.28	($1.06)	($0.16)
Adjusted Weighted Average Basic Shares Outstanding	494M	492.30M	0.00	487.20M	441.40M	369M	365.64M	293.30M	293.30M
Adjusted Diluted Earnings per Share	$0.68	($2.50)	$0.00	($0.97)	($1.27)	$0.18	$0.28	($1.06)	($0.16)
Adjusted Weighted Average Diluted Shares Outstanding	497.30M	492.30M	0.00	487.20M	441.40M	370.30M	365.64M	293.30M	293.30M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.28	($1.06)	($0.16)
Adjusted Weighted Average Basic & Diluted Shares Outstanding	494.61M	492.97M	0.00	473.19M	472.17M	398.53M	313.70M	293.30M	293.30M
Normalized Net Operating Profit after Tax (NOPAT)	161	176	246	209	-57	323	207	100	198
Normalized NOPAT Margin	3.64%	3.98%	5.59%	4.39%	-1.75%	10.53%	6.74%	3.45%	6.80%
Pre Tax Income Margin	10.99%	-27.05%	-1.63%	-11.99%	-20.70%	2.54%	3.72%	-8.05%	-0.77%
Debt Service Ratios	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	3.08	-3.31	0.70	-1.42	-3.51	1.99	4.85	0.00	0.00
NOPAT to Interest Expense	0.24	-2.32	0.49	-0.99	-3.29	2.04	3.68	0.00	0.00
EBIT Less CapEx to Interest Expense	2.45	-3.82	-0.01	-2.09	-3.93	0.22	0.63	0.00	0.00
NOPAT Less CapEx to Interest Expense	-0.38	-2.83	-0.22	-1.67	-3.71	0.27	-0.55	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Elanco Animal Health's official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-1.00%	-1.45%	-3.56%	12.02%	-4.14%	5.18%	4.09%	-10.04%	2.53%	-11.51%	-9.28%
EBITDA Growth	6.97%	-618.28%	192.37%	13.37%	-29.28%	-32.61%	-565.57%	-23.21%	13.86%	28.97%	81.19%
EBIT Growth	28.21%	-728.21%	160.20%	760.00%	-54.65%	-160.00%	-6,506.25%	-109.43%	35.43%	55.22%	122.86%
NOPAT Growth	-46.09%	-728.21%	156.58%	760.00%	20.50%	-160.00%	-6,450.00%	-110.64%	86.66%	55.22%	122.86%
Net Income Growth	109.38%	94.33%	133.21%	48.45%	-68.93%	-161.11%	-1,586.15%	-870.00%	101.96%	50.00%	37.50%
EPS Growth	116.67%	96.55%	132.88%	50.00%	-71.43%	-163.64%	-1,607.69%	-900.00%	110.00%	52.17%	38.10%
Operating Cash Flow Growth	-300.00%	12.74%	-18.18%	227.87%	101.38%	1,107.69%	4.76%	-80.45%	-133.87%	-94.17%	112.36%
Free Cash Flow Firm Growth	-73.38%	15.12%	946.60%	706.65%	549.99%	178.45%	-114.35%	-150.67%	15.56%	-54.94%	588.25%
Invested Capital Growth	-5.21%	-14.56%	-11.00%	-19.37%	-17.88%	-8.88%	-4.20%	3.30%	-1.66%	-3.10%	-10.15%
Revenue Q/Q Growth	16.96%	-0.97%	-13.01%	-1.74%	16.43%	-3.09%	1.04%	-15.91%	27.74%	-4.09%	-12.68%
EBITDA Q/Q Growth	154.15%	-161.25%	303.59%	-20.08%	139.22%	110.92%	-595.35%	-50.14%	150.00%	-24.59%	-18.30%
EBIT Q/Q Growth	115.48%	-204.70%	1,769.70%	-57.69%	213.04%	92.39%	-20,400.00%	-102.91%	673.33%	-287.50%	-69.81%
NOPAT Q/Q Growth	127.66%	-212.37%	1,642.07%	-88.89%	530.64%	92.32%	-20,220.00%	-102.03%	922.00%	-287.50%	-65.96%
Net Income Q/Q Growth	937.50%	-102.20%	828.00%	-256.25%	122.70%	87.14%	-1,029.90%	-194.17%	290.74%	16.92%	-550.00%
EPS Q/Q Growth	1,400.00%	-101.37%	830.00%	-266.67%	120.69%	86.94%	-1,010.00%	-195.24%	290.91%	15.38%	-550.00%
Operating Cash Flow Q/Q Growth	-102.26%	9.26%	-19.00%	9,900.00%	-98.73%	-20.71%	224.59%	142.07%	-1,215.38%	-93.12%	-39.42%
Free Cash Flow Firm Q/Q Growth	-44.60%	-26.25%	-34.20%	-0.07%	136.04%	642.37%	52.85%	-207.06%	1.71%	-72.05%	66.47%
Invested Capital Q/Q Growth	3.14%	-4.24%	-1.75%	-2.31%	-7.04%	-0.25%	-10.99%	-0.51%	3.15%	4.87%	-4.02%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	57.33%	50.88%	52.23%	58.19%	57.26%	50.14%	54.40%	58.94%	60.70%	54.47%	54.00%
EBITDA Margin	21.88%	-47.25%	76.41%	16.47%	20.25%	8.99%	-79.78%	16.27%	27.45%	14.02%	17.84%
Operating Margin	9.39%	-63.33%	60.00%	2.79%	6.47%	-7.54%	-95.13%	-0.47%	14.40%	-3.05%	1.56%
EBIT Margin	8.38%	-63.33%	59.90%	2.79%	6.47%	-7.54%	-95.97%	-0.47%	13.68%	-3.05%	1.56%
Profit (Net Income) Margin	5.62%	-0.78%	35.34%	-4.22%	2.66%	-13.62%	-102.62%	-9.18%	8.19%	-5.49%	-6.34%
Tax Burden Percent	111.67%	15.69%	65.12%	156.25%	266.67%	111.02%	99.91%	122.78%	95.37%	60.67%	147.73%
Interest Burden Percent	60.00%	7.89%	90.60%	-96.97%	15.38%	162.82%	107.02%	1,580.00%	62.79%	296.67%	-275.00%
Effective Tax Rate	-11.67%	0.00%	34.88%	0.00%	-166.67%	0.00%	0.00%	0.00%	4.63%	0.00%	0.00%
Return on Invested Capital (ROIC)	4.40%	-18.23%	15.77%	0.74%	6.28%	-1.91%	-24.37%	-0.11%	4.59%	-0.73%	0.38%
ROIC Less NNEP Spread (ROIC-NNEP)	3.06%	-8.65%	14.96%	-0.68%	2.92%	-3.49%	-31.38%	-1.77%	3.38%	-1.32%	-0.96%
Return on Net Nonoperating Assets (RNNOA)	2.14%	-6.51%	11.12%	-0.52%	2.26%	-2.82%	-26.75%	-1.37%	2.57%	-0.99%	-0.75%
Return on Equity (ROE)	6.54%	-24.74%	26.89%	0.22%	8.53%	-4.73%	-51.13%	-1.48%	7.16%	-1.72%	-0.37%
Cash Return on Invested Capital (CROIC)	6.06%	16.24%	14.58%	15.63%	13.68%	4.03%	-0.81%	-2.37%	2.80%	4.06%	11.41%
Operating Return on Assets (OROA)	2.75%	-20.84%	19.32%	0.85%	1.90%	-2.23%	-28.61%	-0.13%	3.80%	-0.84%	0.45%
Return on Assets (ROA)	1.84%	-0.26%	11.39%	-1.28%	0.78%	-4.03%	-30.59%	-2.53%	2.27%	-1.51%	-1.83%
Return on Common Equity (ROCE)	6.54%	-24.74%	26.89%	0.22%	8.53%	-4.73%	-51.13%	-1.48%	7.16%	-1.72%	-0.37%
Return on Equity Simple (ROE_SIMPLE)	5.87%	0.00%	3.14%	-21.12%	-21.50%	0.00%	-18.65%	-1.52%	-0.35%	0.00%	-1.96%
Net Operating Profit after Tax (NOPAT)	125	-452	402	23	208	-55	-711	-3.50	173	-21	11
NOPAT Margin	10.48%	-44.33%	39.07%	1.95%	17.26%	-5.28%	-66.59%	-0.33%	13.73%	-2.13%	1.09%
Net Nonoperating Expense Percent (NNEP)	1.34%	-9.58%	0.82%	1.42%	3.36%	1.58%	7.01%	1.66%	1.21%	0.59%	1.35%
Return On Investment Capital (ROIC_SIMPLE)	1.16%	-4.34%	-	-	-	-0.46%	-	-	-	-0.16%	-
Cost of Revenue to Revenue	42.67%	49.12%	47.77%	41.81%	42.74%	49.86%	45.60%	41.06%	39.30%	45.53%	46.00%
SG&A Expenses to Revenue	28.58%	29.41%	31.36%	29.90%	27.97%	28.21%	29.31%	33.40%	26.01%	30.59%	29.04%
R&D to Revenue	7.88%	7.94%	8.45%	7.52%	7.22%	7.63%	8.05%	7.66%	6.44%	8.13%	7.60%
Operating Expenses to Revenue	47.95%	114.22%	-7.77%	55.41%	50.79%	57.68%	149.53%	59.41%	46.30%	57.52%	52.44%
Earnings before Interest and Taxes (EBIT)	100	-646	617	33	78	-78	-1,025	-5.00	172	-30	16
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	261	-482	787	195	244	93	-852	172	345	138	183
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.82	0.98	1.11	1.20	1.32	1.18	0.90	0.67	0.62	0.80	0.87
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	1.17	1.35	1.63	1.59	1.84	1.66	1.27	1.15	1.04	1.31	1.30
Price to Earnings (P/E)	13.92	17.71	35.42	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	7.18%	5.65%	2.82%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.89	0.99	1.07	1.17	1.24	1.10	0.95	0.81	0.78	0.88	0.93
Enterprise Value to Revenue (EV/Rev)	2.06	2.22	2.50	2.76	3.08	2.89	2.54	2.46	2.32	2.56	2.50
Enterprise Value to EBITDA (EV/EBITDA)	6.49	7.10	8.43	0.00	0.00	0.00	0.00	12.57	11.56	13.26	13.81
Enterprise Value to EBIT (EV/EBIT)	12.22	13.61	17.09	0.00	0.00	0.00	0.00	65.74	48.24	66.78	85.79
Enterprise Value to NOPAT (EV/NOPAT)	121.10	171.16	34.36	0.00	0.00	0.00	0.00	93.92	68.91	95.40	122.56
Enterprise Value to Operating Cash Flow (EV/OCF)	17.01	18.19	21.36	22.25	32.16	47.10	87.23	90.25	27.97	24.97	17.11
Enterprise Value to Free Cash Flow (EV/FCFF)	14.24	5.61	6.92	6.69	8.19	25.92	0.00	0.00	27.76	21.40	7.71
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.69	0.71	0.67	0.96	0.95	0.93	0.96	0.82	0.80	0.80	0.87
Long-Term Debt to Equity	0.68	0.70	0.66	0.92	0.95	0.92	0.96	0.81	0.75	0.75	0.82
Financial Leverage	0.70	0.75	0.74	0.77	0.77	0.81	0.85	0.77	0.76	0.76	0.78
Leverage Ratio	2.17	2.19	2.18	2.21	2.20	2.21	2.27	2.16	2.12	2.16	2.18
Compound Leverage Factor	1.30	0.17	1.98	-2.15	0.34	3.60	2.43	34.07	1.33	6.41	-6.01
Debt to Total Capital	40.89%	41.48%	40.05%	48.86%	48.77%	48.13%	49.07%	44.96%	44.59%	44.46%	46.66%
Short-Term Debt to Total Capital	0.41%	0.42%	0.40%	1.83%	0.32%	0.32%	0.32%	0.29%	2.82%	2.96%	3.12%
Long-Term Debt to Total Capital	40.48%	41.06%	39.64%	47.02%	48.45%	47.81%	48.74%	44.67%	41.77%	41.51%	43.55%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	59.11%	58.52%	59.95%	51.14%	51.23%	51.87%	50.93%	55.04%	55.41%	55.54%	53.34%
Debt to EBITDA	3.13	3.12	3.30	-18.25	-17.26	-25.78	-33.01	7.16	6.74	6.86	7.20
Net Debt to EBITDA	2.79	2.78	2.93	-16.91	-16.23	-24.21	-30.95	6.72	6.39	6.45	6.64
Long-Term Debt to EBITDA	3.10	3.09	3.27	-17.57	-17.15	-25.61	-32.79	7.11	6.31	6.40	6.72
Debt to NOPAT	58.48	75.16	13.45	-8.25	-8.07	-8.99	-9.70	53.46	40.19	49.33	63.86
Net Debt to NOPAT	52.00	67.02	11.94	-7.64	-7.58	-8.44	-9.10	50.22	38.06	46.42	58.89
Long-Term Debt to NOPAT	57.89	74.40	13.32	-7.94	-8.01	-8.93	-9.64	53.11	37.64	46.05	59.60
Altman Z-Score	0.84	0.70	1.11	0.88	0.95	0.79	0.46	0.71	0.72	0.73	0.77
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.71	2.44	2.55	2.93	3.29	2.75	2.82	2.84	2.25	1.93	1.96
Quick Ratio	1.22	1.03	1.06	1.09	1.16	1.10	1.19	1.24	1.00	0.79	0.92
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	689	1,244	1,686	2,563	2,565	1,080	-199	-423	395	388	1,388
Operating Cash Flow to CapEx	-6.15%	376.60%	385.71%	588.24%	8.33%	382.93%	600.00%	145.24%	-604.17%	16.88%	525.00%
Free Cash Flow to Firm to Interest Expense	17.23	27.04	29.08	39.43	38.86	16.13	-2.77	-5.71	6.17	6.26	23.14
Operating Cash Flow to Interest Expense	-0.10	3.85	2.79	3.08	0.03	2.34	2.75	0.82	-2.27	0.21	3.15
Operating Cash Flow Less CapEx to Interest Expense	-1.73	2.83	2.07	2.55	-0.33	1.73	2.29	0.26	-2.64	-1.03	2.55
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.33	0.33	0.32	0.30	0.29	0.30	0.30	0.28	0.28	0.28	0.29
Accounts Receivable Turnover	4.14	4.68	4.37	3.90	3.73	4.39	4.04	3.68	3.62	4.35	4.30
Inventory Turnover	1.24	1.21	1.21	1.22	1.21	1.18	1.23	1.22	1.29	1.32	1.45
Fixed Asset Turnover	4.44	4.40	4.52	4.59	4.48	4.36	4.53	4.39	4.47	4.30	4.59
Accounts Payable Turnover	6.32	7.08	7.27	6.24	5.72	5.85	5.77	4.99	4.85	4.75	5.03
Days Sales Outstanding (DSO)	88.14	77.95	83.55	93.65	97.92	83.13	90.41	99.31	100.91	83.99	84.84
Days Inventory Outstanding (DIO)	295.18	301.49	300.43	299.27	302.36	309.33	296.82	298.64	282.79	277.52	251.62
Days Payable Outstanding (DPO)	57.76	51.57	50.19	58.48	63.86	62.38	63.28	73.08	75.29	76.89	72.63
Cash Conversion Cycle (CCC)	325.56	327.87	333.78	334.44	336.42	330.09	323.95	324.87	308.41	284.61	263.83
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	10,261	9,949	10,390	10,575	10,825	11,645	11,674	13,115	13,182	12,780	12,186
Invested Capital Turnover	0.42	0.41	0.40	0.38	0.36	0.36	0.37	0.34	0.33	0.34	0.35
Increase / (Decrease) in Invested Capital	-564	-1,696	-1,284	-2,540	-2,357	-1,135	-512	419	-222	-409	-1,377
Enterprise Value (EV)	9,101	9,840	11,129	12,391	13,443	12,765	11,078	10,650	10,323	11,286	11,325
Market Capitalization	5,193	5,987	7,262	7,131	8,023	7,343	5,538	4,955	4,621	5,795	5,884
Book Value per Share	$12.84	$12.33	$13.20	$12.02	$12.28	$12.63	$12.45	$15.06	$15.22	$15.37	$14.23
Tangible Book Value per Share	($3.62)	($4.04)	($4.27)	($5.14)	($5.31)	($6.83)	($6.58)	($6.70)	($6.86)	($7.48)	($7.88)
Total Capital	10,748	10,417	10,880	11,618	11,821	11,997	12,043	13,482	13,500	13,125	12,646
Total Debt	4,395	4,321	4,357	5,676	5,765	5,774	5,909	6,062	6,020	5,836	5,901
Total Long-Term Debt	4,351	4,277	4,313	5,463	5,727	5,736	5,870	6,023	5,639	5,448	5,507
Net Debt	3,908	3,853	3,867	5,260	5,420	5,422	5,540	5,695	5,702	5,491	5,441
Capital Expenditures (CapEx)	65	47	42	34	24	41	33	42	24	77	36
Debt-free, Cash-free Net Working Capital (DFCFNWC)	1,728	1,476	1,599	2,438	2,511	1,852	1,970	2,040	2,033	1,620	1,475
Debt-free Net Working Capital (DFNWC)	2,215	1,944	2,089	2,854	2,856	2,204	2,339	2,407	2,351	1,965	1,935
Net Working Capital (NWC)	2,171	1,900	2,045	2,641	2,818	2,166	2,300	2,368	1,970	1,577	1,541
Net Nonoperating Expense (NNE)	58	-444	38	73	176	86	385	94	70	33	76
Net Nonoperating Obligations (NNO)	3,908	3,853	3,867	4,633	4,769	5,422	5,540	5,695	5,702	5,491	5,441
Total Depreciation and Amortization (D&A)	161	164	170	162	166	171	173	177	173	168	167
Debt-free, Cash-free Net Working Capital to Revenue	39.03%	33.25%	35.90%	54.27%	57.53%	41.93%	45.12%	47.18%	45.77%	36.73%	32.50%
Debt-free Net Working Capital to Revenue	50.03%	43.79%	46.90%	63.54%	65.43%	49.90%	53.57%	55.67%	52.93%	44.55%	42.63%
Net Working Capital to Revenue	49.04%	42.80%	45.91%	58.79%	64.56%	49.04%	52.68%	54.76%	44.35%	35.75%	33.95%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.14	($0.02)	$0.74	($0.10)	$0.06	($0.29)	($2.22)	($0.20)	$0.21	($0.11)	($0.10)
Adjusted Weighted Average Basic Shares Outstanding	495.10M	494M	494.30M	494.20M	493.20M	492.30M	492.70M	492.60M	491.10M	488.30M	488.40M
Adjusted Diluted Earnings per Share	$0.13	($0.01)	$0.73	($0.10)	$0.06	($0.29)	($2.22)	($0.20)	$0.21	($0.11)	($0.10)
Adjusted Weighted Average Diluted Shares Outstanding	499.10M	497.30M	497.70M	494.20M	496M	492.30M	492.70M	492.60M	492.80M	488.30M	488.40M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	496.65M	494.61M	494.35M	494.33M	494.18M	492.97M	492.80M	492.68M	492.55M	491.54M	474.21M
Normalized Net Operating Profit after Tax (NOPAT)	85	-447	413	79	87	-29	29	21	211	0.70	29
Normalized NOPAT Margin	7.10%	-43.85%	40.14%	6.68%	7.20%	-2.84%	2.75%	1.99%	16.77%	0.07%	2.87%
Pre Tax Income Margin	5.03%	-5.00%	54.27%	-2.70%	1.00%	-12.27%	-102.72%	-7.47%	8.59%	-9.04%	-4.29%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	2.50	-14.04	10.64	0.51	1.18	-1.16	-14.24	-0.07	2.69	-0.48	0.27
NOPAT to Interest Expense	3.13	-9.83	6.94	0.36	3.15	-0.81	-9.88	-0.05	2.70	-0.34	0.19
EBIT Less CapEx to Interest Expense	0.88	-15.07	9.91	-0.02	0.82	-1.78	-14.69	-0.64	2.31	-1.73	-0.33
NOPAT Less CapEx to Interest Expense	1.50	-10.85	6.21	-0.17	2.79	-1.43	-10.34	-0.61	2.32	-1.58	-0.41
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Elanco Animal Health's Financials

When does Elanco Animal Health's financial year end?

According to the most recent income statement we have on file, Elanco Animal Health's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Elanco Animal Health's net income changed over the last 8 years?

Elanco Animal Health's net income appears to be on an upward trend, with a most recent value of $338 million in 2024, falling from -$47.90 million in 2016. The previous period was -$1.23 billion in 2023. Check out Elanco Animal Health's forecast to explore projected trends and price targets.

What is Elanco Animal Health's operating income?

Elanco Animal Health's total operating income in 2024 was $83 million, based on the following breakdown:

Total Gross Profit: $2.44 billion
Total Operating Expenses: $2.35 billion

How has Elanco Animal Health revenue changed over the last 8 years?

Over the last 8 years, Elanco Animal Health's total revenue changed from $2.91 billion in 2016 to $4.44 billion in 2024, a change of 52.4%.

How much debt does Elanco Animal Health have?

Elanco Animal Health's total liabilities were at $6.52 billion at the end of 2024, a 19.9% decrease from 2023, and a 461.9% increase since 2017.

How much cash does Elanco Animal Health have?

In the past 7 years, Elanco Animal Health's cash and equivalents has ranged from $323.40 million in 2017 to $638 million in 2021, and is currently $468 million as of their latest financial filing in 2024.

How has Elanco Animal Health's book value per share changed over the last 8 years?

Over the last 8 years, Elanco Animal Health's book value per share changed from 0.00 in 2016 to 12.33 in 2024, a change of 1,233.1%.

Related Companies

This page (NYSE:ELAN) was last updated on 5/28/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Elanco Animal Health (ELAN) Financials

Frequently Asked Questions About Elanco Animal Health's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Elanco Animal Health (ELAN) Financials

Annual Income Statements for Elanco Animal Health

Quarterly Income Statements for Elanco Animal Health

Annual Cash Flow Statements for Elanco Animal Health

Quarterly Cash Flow Statements for Elanco Animal Health

Annual Balance Sheets for Elanco Animal Health

Quarterly Balance Sheets for Elanco Animal Health

Annual Metrics And Ratios for Elanco Animal Health

Quarterly Metrics And Ratios for Elanco Animal Health

Frequently Asked Questions About Elanco Animal Health's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools